Effect of miR-21 Inhibitor Coated with Ferric Oxide on Ovarian Cancer Cells Through Mitogen-Activated Protein Kinase Signaling Pathway

IF 2.9 4区 医学 Q1 Medicine Journal of biomedical nanotechnology Pub Date : 2023-12-01 DOI:10.1166/jbn.2023.3726
Weiwei Qian, Wen Feng
{"title":"Effect of miR-21 Inhibitor Coated with Ferric Oxide on Ovarian Cancer Cells Through Mitogen-Activated Protein Kinase Signaling Pathway","authors":"Weiwei Qian, Wen Feng","doi":"10.1166/jbn.2023.3726","DOIUrl":null,"url":null,"abstract":"Ovarian cancer (OC) incidence has in recent years been on the rise among common gynecological cancers. Iron oxide nanoparticles (IONPs), as emerging nanomedicines, have been widely used in research on cancer therapy. However, with in-depth research on microRNA (miRNA), the effect of\n combining miRNA with nanoparticles on ovarian cancer is not yet clear. We deeply explored the mechanism of IONPs loading miRNA to regulate ovarian cancer cells. In this study, novelmiR-21 inhibitor-IONPs nanoparticles were prepared by loading miR-21 inhibitor into IONPs. Electron microscopy\n was used to observe nano-encapsulation and miR-21 expression was measured along with analysis of cell proliferation, apoptosis by flow cytometry, and phosphorylation of apoptotic proteins and mitogen-activated protein kinase (MAPK) signaling pathways by Western blot. Our results showed that\n miR-21 inhibitor-IONPs reduced miR-21 expression, thereby inhibiting ovarian cancer cells activities and promoting apoptosis. miR-21 inhibitor-IONPs also inhibited p-p38MAPK and p-ERK levels, which were increased after addition of MAPK agonist (U-46619). Moreover, ovarian cancer cell proliferation\n increased and apoptosis decreased. miR-21 inhibitor-IONPs can thus inhibit MAPK signaling, thereby reducing the activities of ovarian cancer cells. This study provides theoretical support for application of miR-21 inhibitor-IONPs as novel nanoparticles for the treatment of ovarian cancer.","PeriodicalId":15260,"journal":{"name":"Journal of biomedical nanotechnology","volume":" 77","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical nanotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1166/jbn.2023.3726","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Ovarian cancer (OC) incidence has in recent years been on the rise among common gynecological cancers. Iron oxide nanoparticles (IONPs), as emerging nanomedicines, have been widely used in research on cancer therapy. However, with in-depth research on microRNA (miRNA), the effect of combining miRNA with nanoparticles on ovarian cancer is not yet clear. We deeply explored the mechanism of IONPs loading miRNA to regulate ovarian cancer cells. In this study, novelmiR-21 inhibitor-IONPs nanoparticles were prepared by loading miR-21 inhibitor into IONPs. Electron microscopy was used to observe nano-encapsulation and miR-21 expression was measured along with analysis of cell proliferation, apoptosis by flow cytometry, and phosphorylation of apoptotic proteins and mitogen-activated protein kinase (MAPK) signaling pathways by Western blot. Our results showed that miR-21 inhibitor-IONPs reduced miR-21 expression, thereby inhibiting ovarian cancer cells activities and promoting apoptosis. miR-21 inhibitor-IONPs also inhibited p-p38MAPK and p-ERK levels, which were increased after addition of MAPK agonist (U-46619). Moreover, ovarian cancer cell proliferation increased and apoptosis decreased. miR-21 inhibitor-IONPs can thus inhibit MAPK signaling, thereby reducing the activities of ovarian cancer cells. This study provides theoretical support for application of miR-21 inhibitor-IONPs as novel nanoparticles for the treatment of ovarian cancer.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
涂有氧化铁的 miR-21 抑制剂通过丝裂原活化蛋白激酶信号通路对卵巢癌细胞的影响
近年来,卵巢癌(OC)的发病率在常见妇科癌症中呈上升趋势。氧化铁纳米颗粒作为一种新兴的纳米药物,在癌症治疗研究中得到了广泛的应用。然而,随着对microRNA (miRNA)研究的深入,miRNA与纳米颗粒联合治疗卵巢癌的效果尚不明确。我们深入探讨了IONPs装载miRNA调控卵巢癌细胞的机制。在本研究中,通过将miR-21抑制剂装载到IONPs中,制备了新型miR-21抑制剂-IONPs纳米颗粒。电镜观察纳米包封,检测miR-21的表达,流式细胞术分析细胞增殖和凋亡,Western blot分析凋亡蛋白和丝裂原活化蛋白激酶(MAPK)信号通路的磷酸化情况。我们的研究结果表明,miR-21抑制剂- ionps降低了miR-21的表达,从而抑制卵巢癌细胞的活性,促进细胞凋亡。miR-21抑制剂- ionps也抑制p-p38MAPK和p-ERK水平,在添加MAPK激动剂(U-46619)后,p-p38MAPK和p-ERK水平升高。此外,卵巢癌细胞增殖增加,凋亡减少。因此,miR-21抑制剂- ionps可以抑制MAPK信号,从而降低卵巢癌细胞的活性。本研究为miR-21抑制剂- ionps作为新型纳米颗粒治疗卵巢癌提供了理论支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.30
自引率
17.20%
发文量
145
审稿时长
2.3 months
期刊介绍: Information not localized
期刊最新文献
Mequinol-Loaded Nano Clay Drug Carriers in a Gelatin Hydrogel for Wound Healing: An Antiinflammatory and Antioxidant Treatment Modality Resveratrol Inhibited Nanoparticles Stromal Interaction Molecule 2 in Regulating miR-20b-5p Signaling Pathway to Improve Mitochondrial Function During Myocardial Ischemia-Reperfusion Injury A Hierarchically Micro- and Nanofibrous Hybrid Hydrogel Derived from Decellularized Skin Matrix with High Bioactivity and Tunable Mechanical Properties for Accelerated Wound Healing Sport Medicine Principles Augment Healing Response in Spinal Cord Injury in a Rat Model Treated with a Curcumin-Loaded Nanocomposite Hydrogel Polyacrylic Acid-Modified Superparamagnetic Iron Oxide Nanoparticles Differentiate Between Hyperplastic and Metastatic Breast Cancer Lymph Nodes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1